PTH and left ventricular hypertrophy: Although both trials confirmed successful biochemical control of SHPT—with PRIMO achieving significant PTH suppression and J-DAVID enrolling patients with already controlled PTH levels (80 pg/mL)—they consistently showed no benefit in reducing left ventricular hypertrophy, major adverse cardiovascular events, or overall mortality.